Indonesia’s headline CPI edged down marginally in June to 3.28 percent y/y. Although core and volatile food inflation rose, this was offset by lower administered price inflation. The big picture is that inflation remains under control and comfortably within the central bank’s 2.5-4.5 percent target band, ANZ Research reported.
Most major categories recorded a pick-up in annual inflation, with healthcare and transport as the main exceptions. The slowdown in transport inflation, to 1.91 percent y/y in June from 3.58 percent y/y in May, was the main driver behind the pullback in headline inflation.
In sequential terms, headline CPI rose by 0.55 percent m/m in June, easing from the 0.68 percent increase in the prior month. The pace of increase in clothing and housing prices picked up, but these were offset by a fall in transport prices and a slower pace of increase in food prices.
Core CPI, which excludes volatile food and government-controlled prices, rose by 0.37 percent m/m in June, up from 0.27 percent in May. In y/y terms, core inflation rose to a 26-month high of 3.25 percent, but even then, it remains contained by historical standards.
"We continue to see scope for the policy rate to be lowered by 75bps over the next one year, with the first potentially materialising in July provided that IDR stability is maintained," ANZ Research commented in the report.


U.S.-India Trade Framework Signals Major Shift in Tariffs, Energy, and Supply Chains
South Africa Eyes ECB Repo Lines as Inflation Eases and Rate Cuts Loom
Silver Prices Plunge in Asian Trade as Dollar Strength Triggers Fresh Precious Metals Sell-Off
Trump’s Inflation Claims Clash With Voters’ Cost-of-Living Reality
Bank of Japan Signals Readiness for Near-Term Rate Hike as Inflation Nears Target
Dollar Near Two-Week High as Stock Rout, AI Concerns and Global Events Drive Market Volatility
Fed Confirms Rate Meeting Schedule Despite Severe Winter Storm in Washington D.C.
Japan Economy Poised for Q4 2025 Growth as Investment and Consumption Hold Firm
Japanese Pharmaceutical Stocks Slide as TrumpRx.gov Launch Sparks Market Concerns 



